# Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

## **CONVEYING PARTY DATA**

Name	Execution Date
Barr Laboratories, Inc.	09/17/2008

### **RECEIVING PARTY DATA**

Name:	DURAMED PHARMACEUTICALS, INC.,
Street Address:	5040 Duramed Drive
City:	Cincinnati
State/Country:	ОНЮ
Postal Code:	45213-2520

### PROPERTY NUMBERS Total: 4

Property Type	Number
Patent Number:	6660726
Patent Number:	6844334
Patent Number:	7179799
Application Number:	11671718

### **CORRESPONDENCE DATA**

Fax Number: (919)854-1401

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 919-854-1400

Email: brosser@myersbigel.com

Correspondent Name: Myers Bigel Sibley & Sajovec, PA

Address Line 1: 4140 Parklake Avenue

Address Line 2: Suite 600

Address Line 4: Raleigh, NORTH CAROLINA 27612

ATTORNEY DOCKET NUMBER:	9448-16;16CT;16CT2;16CT3
NAME OF SUBMITTER:	Betty-Lou Rosser

PATENT REEL: 021561 FRAME: 0978

500654803

**2**0999

CH \$160.0

Total Attachments: 3 source=944816Assn#page1.tif source=944816Assn#page2.tif source=944816Assn#page3.tif

> PATENT REEL: 021561 FRAME: 0979

## **ASSIGNMENT**

THIS ASSIGNMENT, made by Barr Laboratories, Inc., a Delaware corporation having a principal place of business at 400 Chestnut Ridge Road, Woodcliff Lake, State of New Jersey 07677, hereinafter referred to as assignor;

WITNESSETH: That,

WHEREAS, the above-named corporation is the owner of the entire right, title, and interest in and to certain new and useful improvements related to estrogenic compounds for which applications for United States Letters Patent and for foreign patents have been filed and are set forth in Schedule A; and

WHEREAS, **DURAMED PHARMACEUTICALS**, **INC**, a Delaware corporation having a principal place of business at 5040 Duramed Drive, Cincinnati, State of Ohio 45213-2520, hereinafter referred to as assignee, is desirous of acquiring the entire right, title, and interest in and to said invention as described in said applications, and in and to any and all patents that have or which shall be granted therefor in the United States of America and all foreign countries;

NOW, THEREFORE, To All Whom It May Concern, be it known that for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the above assignor has sold and by these presents does hereby sell, assign, transfer, and convey unto the said assignee, its successors and assigns, the entire right, title, and interest in and to the said invention and application, and in and to any and all continuations, continuations-in-part, or divisions thereof, and in and to any and all Letters Patent of the United States of America and all foreign countries or reissues or other forms of protection thereof which may be granted therefor or thereon, for the full end of the term for which said Letters Patent may be granted along with any term extensions thereon or therefor, together with the right to claim the priority of said application in all foreign countries in accordance with the International Convention, the same to be held and enjoyed by said assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by assignor if this assignment and sale had not been made.

The assignor hereby requests that said Letters Patent be issued in accordance with this assignment.

The assignor further covenants and agrees that, at the time of the execution and

delivery of these presents, it possesses full title to the invention and patent application thereon as earlier identified, and that it has the unencumbered right and authority to make this assignment.

The assignor further covenants and agrees to promptly communicate to said assignee or its representatives any facts known to the assignor relating to said invention, to testify in any interference or legal proceedings involving said invention, to execute any additional papers which may be requested to confirm the right of the assignee, its representatives, successors, or assigns to secure patent or similar protection for the said invention in all countries and to vest in the assignee complete title to the said invention and Letters Patent, without further compensation, but at the expense of said assignee, its successors, assigns, and other legal representatives; and the assignor hereby instructs, and further covenants and agrees to bind its legal representatives and assigns, to do same, without further compensation, but at the expense of said assignee or its representatives.

but at the expense of said a	ssignee or its representatives.	
IN WITNESS WHE	EREOF, the assignor has caused this assignment to be executed	
this 17 day of Ju	By: flad france (SEAL)  Its: Vice President and Chief Infellet	
	Its: VICe President and Chief Infellet	سائط
STATE OF	) ss:	
COUNTY OF	)	
Before me personal	ly appeared <u>Heidi L. Kraus</u> , to me known to be the person	
	ited the foregoing instrument, and s/he acknowledged to me that	
s/he executed the same for	the purposes therein stated, this	
September, 2008.	Barbara A. Carpennt	
	Notary Public	
(SEAL)		
My Commission Expires: _	12/27/11	
	BARBARA A. CARPENITO	

BARBARA A. CARPENITO
Notary Public of New Jersey
ID # 2282614
My Commission Exp. Dec. 27, 2011
Page 2 of 3

PATENT REEL: 021561 FRAME: 0981

#### SCHEDULE A

1. U.S. Patent No. 6,660,726 Issued: December 9, 2003

Recordation of Assignment: January 16, 2004

Reel/Frame: 014896/0267

Assignors: Endeavor Pharmaceuticals, Inc.

Assignee: Barr Laboratories, Inc.

2. U.S. Patent No. 6,844,334

Issued: January 18, 2005

Recordation of Assignment: January 16, 2004

Reel/Frame: 014896/0229

Assignors: Endeavor Pharmaceuticals, Inc.

Assignee: Barr Laboratories, Inc.

3. U.S. Patent No. 7,179,799

Issued: February 20, 2007

Recordation of Assignment: January 16, 2004

Reel/Frame: 014897/0861

Assignors: Endeavor Pharmaceuticals, Inc.

Assignee: Barr Laboratories, Inc.

4. U.S. Patent Application No. 11/671,718

Filed: February 6, 2007

Recordation of Assignment: January 16, 2004

Reel/Frame: 014897/0861

Assignors: Endeavor Pharmaceuticals, Inc.

Assignee: Barr Laboratories, Inc.

5. Canadian Patent Application No. 2402667

Filed: March 9, 2001

6. German Patent No. 1263770

Issued: November 7, 2007

7. Britain Patent No. 1263770

Issued: November 7, 2007

8. Netherlands Patent No. 1263770

Issued: November 7, 2007

Page 3 of 3

PATENT REEL: 021561 FRAME: 0982